EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Myo-Inositol in Pregnancy: Implications for Acne Management

Daniela Baboun, Marita Yaghi, Jennifer Keelin, Daniella M Hernandez-Bueso, Valery Fernandez Fernandez, Jonette Keri

Journal of Drugs in Dermatology · 01.07.2026 · 25 (7) · 611-614

DOI: 10.36849/jdd.9783 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.06.2026. Verfasst von Daniela Baboun und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Inositol, Acne Vulgaris, Pregnancy Complications.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acne vulgaris is common during pregnancy and presents unique therapeutic challenges due to fetal safety considerations and restrictions on conventional acne medications. Adjunctive strategies that target hormonal and metabolic contributors to acne without teratogenic risk are therefore of particular relevance to dermatologic care. OBJECTIVE: To review the evidence supporting myo-inositol as an adjunctive option for pregnancy-related acne and contextualize its dermatologic relevance within associated metabolic, endocrine, and psychosocial conditions. METHODS: A literature review of randomized controlled trials, systematic reviews, meta-analyses, observational studies, and mechanistic investigations evaluating myo-inositol in acne, polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), preeclampsia, fertility, mental health, sleep, and topical applications was conducted. RESULTS: Myo-inositol supplementation has been associated with reductions in acne severity, especially in patients with PCOS, along with improvements in insulin sensitivity and key metabolic parameters. In pregnancy, myo-inositol has been linked to reduced incidence of GDM, favorable endothelial and metabolic markers relevant to preeclampsia, and improved reproductive outcomes. Additional evidence suggests benefits for mood and sleep, factors that may indirectly influence acne. Available data support a favorable maternal and fetal safety profile, but evidence for topical myo-inositol in acne remains limited. CONCLUSION: Myo-inositol may represent a safe adjunctive option for acne management during pregnancy, particularly in patients with metabolic or hyperandrogenic features. Although acne-specific pregnancy data are limited, existing mechanistic and safety evidence supports its consideration in dermatologic practice when therapeutic options are restricted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InositolAcne VulgarisPregnancy ComplicationsHumansFemalePregnancyPolycystic Ovary SyndromeDiabetes, Gestational

Substanzen

Inositol

Zitieren

APA

Baboun, D., Yaghi, M., Keelin, J., Hernandez-Bueso, D. M., Fernandez Fernandez, V., & Keri, J. (2026). Myo-Inositol in Pregnancy: Implications for Acne Management. Journal of Drugs in Dermatology, 25(7), 611-614. https://doi.org/10.36849/jdd.9783

Vancouver

Baboun D, Yaghi M, Keelin J, Hernandez-Bueso DM, Fernandez Fernandez V, Keri J. Myo-Inositol in Pregnancy: Implications for Acne Management. Journal of Drugs in Dermatology. 2026;25(7):611-614. doi:10.36849/jdd.9783

BibTeX
@article{Baboun2026,
  author = {Baboun, Daniela and Yaghi, Marita and Keelin, Jennifer and Hernandez-Bueso, Daniella M and Fernandez Fernandez, Valery and Keri, Jonette},
  title = {Myo-Inositol in Pregnancy: Implications for Acne Management},
  journal = {Journal of Drugs in Dermatology},
  year = {2026},
  volume = {25},
  number = {7},
  pages = {611--614},
  doi = {10.36849/jdd.9783}
}
Kostenlos starten →